Pathological Issues in Dystrophinopathy in the Age of Genetic Therapies

Annual Review of Pathology
Nazima ShahnoorMichael W Lawlor

Abstract

Dystrophinopathy is a class of genetic skeletal muscle disease characterized by myofiber degeneration and regeneration due to insufficient levels or functioning of dystrophin. Pathological evaluation for dystrophinopathy includes the identification of dystrophic skeletal muscle pathology and the immunohistochemical evaluation of dystrophin epitopes, but biopsies have become rare in recent years. However, the evaluation of dystrophin expression in the research setting has become critically important due to recent advances in genetic therapies, including exon skipping and gene therapy. Given the number of these therapies under evaluation in patients, it is likely that the traditional methods of evaluating dystrophinopathy will need to evolve in the near future. This review discusses current muscle biopsy diagnostic practices in dystrophinopathy and further focuses on how these practices have evolved in the context of therapeutic interventions for dystrophinopathy.

References

Jan 1, 1992·Neuromuscular Disorders : NMD·M FaninC Angelini
Dec 1, 1988·Journal of the Neurological Sciences·B A ValentineJ T Blue
Feb 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·G BulfieldK J Moore
Sep 1, 1994·Neuromuscular Disorders : NMD·N J WinandB J Cooper
Sep 1, 1996·British Journal of Rheumatology·F IannoneG S Panayi
Nov 21, 2000·Current Biology : CB·J S Chamberlain, G M Benian
Nov 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·B WangX Xiao
Dec 12, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·D Hartigan-O'ConnorJ S Chamberlain
Mar 5, 2002·Nature Medicine·Scott Q HarperJeffrey S Chamberlain
Jun 17, 2003·Experimental Animals·Yoshiki ShimatsuShin'ichi Takeda
Jul 5, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Patrick DunantHanns Lochmüller
Nov 6, 2004·Science·Aurélie GoyenvalleOlivier Danos
Dec 22, 2004·Human Gene Therapy·Norma B RomeroMichel Fardeau
Feb 21, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jason H WilliamsGordon J Lutz
Nov 14, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Saïd AbesBernard Lebleu
Jun 21, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sue FletcherStephen D Wilton
Dec 28, 2007·The New England Journal of Medicine·Judith C van DeutekomGert-Jan B van Ommen
May 27, 2008·Human Gene Therapy·Michela Alessandra DentiIrene Bozzoni
Jun 12, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Natee JearawiriyapaisarnRyszard Kole
Sep 23, 2008·Proceedings of the National Academy of Sciences of the United States of America·Bo WuQi Long Lu
Jan 28, 2009·Molecular and Cellular Neurosciences·Glen B BanksStanley C Froehner
Feb 17, 2009·Neuromuscular Disorders : NMD·Raffaella WillmannMarkus A Ruegg
Mar 12, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Bo WuQi Long Lu
Mar 17, 2009·Annals of Neurology·Toshifumi YokotaEric Hoffman

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
transgenic
antisense oligonucleotides
flow cytometry
electron microscopy
biopsies

Software Mentioned

ImageJ

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

Journal of Neurology, Neurosurgery, and Psychiatry
F D WorzakD Ripamonti
Acta Paediatrica Taiwanica = Taiwan Er Ke Yi Xue Hui Za Zhi
Y J Jong
Ryōikibetsu shōkōgun shirīzu
A Nakamura, S Takeda
© 2022 Meta ULC. All rights reserved